SM 1542
Alternative Names: SM-1542Latest Information Update: 11 Nov 2023
At a glance
- Originator Beijing StarMab BioMed Technology
- Class Antineoplastics; Immunotherapies; Single-domain antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours